OBJECTIVES: To study vitamin C pharmacokineticsin septic shock. DESIGN: Prospective pharmacokinetic study. SETTING: Two intensive care units. PARTICIPANTS: Twenty-one patients with septic shock enrolled in a randomised trial of high dose vitamin C therapyin septic shock. INTERVENTION: Patients received 1.5 g intravenous vitamin C every 6 hours. Plasma samples were obtained before and at 1, 4 and 6 hours after drug administration, and vitamin C concentrations were measured by high performance liquid chromatography. MAIN OUTCOME MEASURES: Clearance, volume of distribution, and half-life were calculated using noncompartmental analysis. Data are presented as median (interquartile range [IQR]). RESULTS: Of the 11 participants who had plasma collected before any intravenous vitamin C administration, two (18%) were deficient (concentrations < 11 μmol/L) and three (27%) had hypovitaminosis C (concentrations between 11 and 23 μmol/L), with a median concentration 28 μmol/L (IQR, 11-44 μmol/L). Volume of distribution was 23.3 L (IQR, 21.9-27.8 L), clearance 5.2 L/h (IQR, 3.3-5.4 L/h), and half-life 4.3 h (IQR, 2.6-7.5 h). For the participants who had received at least one dose of intravenous vitamin C before sampling, T0 concentration was 258 μmol/L (IQR, 162- 301 μmol/L). Pharmacokinetic parameters for subsequent doses were a median volume of distribution 39.9 L (IQR, 31.4-44.4 L), clearance 3.6 L/h (IQR, 2.6-6.5 L/h), and half-life 6.9 h (IQR, 5.7-8.5 h). CONCLUSION:Intravenous vitamin C (1.5 g every 6 hours) corrects vitamin C deficiency and hypovitaminosis C and provides an appropriate dosing schedule to achieve and maintain normal or elevated vitamin C levels in septic shock.
RCT Entities:
OBJECTIVES: To study vitamin C pharmacokinetics in septic shock. DESIGN: Prospective pharmacokinetic study. SETTING: Two intensive care units. PARTICIPANTS: Twenty-one patients with septic shock enrolled in a randomised trial of high dose vitamin C therapy in septic shock. INTERVENTION: Patients received 1.5 g intravenous vitamin C every 6 hours. Plasma samples were obtained before and at 1, 4 and 6 hours after drug administration, and vitamin C concentrations were measured by high performance liquid chromatography. MAIN OUTCOME MEASURES: Clearance, volume of distribution, and half-life were calculated using noncompartmental analysis. Data are presented as median (interquartile range [IQR]). RESULTS: Of the 11 participants who had plasma collected before any intravenous vitamin C administration, two (18%) were deficient (concentrations < 11 μmol/L) and three (27%) had hypovitaminosis C (concentrations between 11 and 23 μmol/L), with a median concentration 28 μmol/L (IQR, 11-44 μmol/L). Volume of distribution was 23.3 L (IQR, 21.9-27.8 L), clearance 5.2 L/h (IQR, 3.3-5.4 L/h), and half-life 4.3 h (IQR, 2.6-7.5 h). For the participants who had received at least one dose of intravenous vitamin C before sampling, T0 concentration was 258 μmol/L (IQR, 162- 301 μmol/L). Pharmacokinetic parameters for subsequent doses were a median volume of distribution 39.9 L (IQR, 31.4-44.4 L), clearance 3.6 L/h (IQR, 2.6-6.5 L/h), and half-life 6.9 h (IQR, 5.7-8.5 h). CONCLUSION: Intravenous vitamin C (1.5 g every 6 hours) corrects vitamin C deficiency and hypovitaminosis C and provides an appropriate dosing schedule to achieve and maintain normal or elevated vitamin C levels in septic shock.
Authors: Sander Rozemeijer; Harm-Jan de Grooth; Paul W G Elbers; Armand R J Girbes; Corstiaan A den Uil; Eric A Dubois; Evert-Jan Wils; Thijs C D Rettig; Arthur R H van Zanten; Roel Vink; Bas van den Bogaard; Rob J Bosman; Heleen M Oudemans-van Straaten; Angélique M E de Man Journal: Trials Date: 2021-08-18 Impact factor: 2.279
Authors: Tomoko Fujii; Nora Luethi; Paul J Young; Daniel R Frei; Glenn M Eastwood; Craig J French; Adam M Deane; Yahya Shehabi; Ludhmila A Hajjar; Gisele Oliveira; Andrew A Udy; Neil Orford; Samantha J Edney; Anna L Hunt; Harriet L Judd; Laurent Bitker; Luca Cioccari; Thummaporn Naorungroj; Fumitaka Yanase; Samantha Bates; Forbes McGain; Elizabeth P Hudson; Wisam Al-Bassam; Dhiraj Bhatia Dwivedi; Chloe Peppin; Phoebe McCracken; Judit Orosz; Michael Bailey; Rinaldo Bellomo Journal: JAMA Date: 2020-02-04 Impact factor: 56.272
Authors: Patrice Rosengrave; Emma Spencer; Jonathan Williman; Jan Mehrtens; Stacey Morgan; Tara Doyle; Kymbalee Van Der Heyden; Anna Morris; Geoff Shaw; Anitra C Carr Journal: Crit Care Date: 2022-01-25 Impact factor: 9.097
Authors: Ari Moskowitz; David T Huang; Peter C Hou; Jonathan Gong; Pratik B Doshi; Anne V Grossestreuer; Lars W Andersen; Long Ngo; Robert L Sherwin; Katherine M Berg; Maureen Chase; Michael N Cocchi; Jessica B McCannon; Mark Hershey; Ayelet Hilewitz; Maksim Korotun; Lance B Becker; Ronny M Otero; Junior Uduman; Ayan Sen; Michael W Donnino Journal: JAMA Date: 2020-08-18 Impact factor: 56.272
Authors: David C Consoli; Jordan J Jesse; Kelly R Klimo; Adriana A Tienda; Nathan D Putz; Julie A Bastarache; Fiona E Harrison Journal: Nutrients Date: 2020-03-26 Impact factor: 5.717